Market Scenario 

Point-of-care testing market was valued at US$ 46.48 billion in 2024 and is projected to hit the market valuation of US$ 85.55 billion by 2033 at a CAGR of 7.33% during the forecast period 2025–2033.

The point-of-care testing market is witnessing remarkable growth. This surge is fueled by the increasing prevalence of global health challenges, including 537 million individuals living with diabetes, 38.4 million affected by HIV, and 10.6 million tuberculosis cases worldwide. Additionally, the aging population—comprising 727 million people aged 65 and older—has heightened the demand for frequent monitoring of chronic conditions. The COVID-19 pandemic further accelerated the adoption of point-of-care diagnostics, with COVID-19 testing dominating the market. Investments in this space remain robust, as seen with Unitaid’s US$ 30 million funding in September 2022 to enhance diagnostic technologies and improve accessibility across healthcare systems.

Technological advancements are reshaping the point-of-care testing market, particularly in molecular diagnostics, which accounted for 43.0% of the market share in 2023. Lateral flow immunoassays are also emerging as a high-growth segment. Clinics remain the primary end-users due to their role in delivering frontline care, while home healthcare is rapidly expanding, driven by the convenience and affordability it offers patients. Innovations in product development are also transforming the market. For instance, the FDA approved Qvin’s Q-Pad A1c Test System in January 2024, which uses menstrual blood for diabetes monitoring, and Roche introduced three new coagulation tests for oral anticoagulants in February 2024. Over-the-counter (OTC) availability is gaining momentum, with nearly 50 molecular COVID-19 tests approved for home collection among the 278 FDA-authorized tests.

North America leads the point-of-care testing market, holding 51.0% of the market share, thanks to its advanced healthcare infrastructure and the presence of key players like Abbott, Thermo Fisher Scientific, and Siemens Healthineers. Meanwhile, the Asia Pacific region is the fastest-growing market, driven by rising disease prevalence and healthcare advancements in countries like China, India, and Japan. Strategic acquisitions are shaping the competitive landscape, such as Roche’s acquisition of LumiraDx’s platform in January 2024 and Werfen’s US$ 2 billion purchase of Immucor in March 2023. The market is poised for continued growth as decentralized testing becomes a cornerstone of global healthcare, particularly in underserved regions where rapid diagnostics are critical for disease management and prevention. 

To Get more Insights,  Request A Free Sample 

 Market Dynamics 

Driver: Aging Population Driving Demand For Frequent Chronic Disease Monitoring

The global point-of-care testing market is experiencing substantial growth driven by demographic shifts, with 727 million individuals aged 65 and above worldwide requiring continuous health monitoring. By 2030, this demographic will reach 994 million, representing a significant expansion in the patient population needing regular diagnostic assessments. Chronic conditions such as diabetes, cardiovascular diseases, and kidney disorders affect 4 out of 5 older adults, necessitating frequent testing to manage medication dosages, monitor disease progression, and prevent complications. The financial burden of chronic disease management reaches US$ 3.8 trillion annually in healthcare expenditures globally, pushing healthcare systems to adopt more efficient diagnostic solutions. In the global point-of-care testing market, aging populations in developed nations particularly drive demand, with Japan leading where 30 million citizens are over 65, followed by Germany with 18 million and Italy with 14 million elderly residents requiring regular health monitoring.

The convergence of aging demographics and chronic disease prevalence creates unprecedented demand for accessible diagnostic solutions outside traditional laboratory settings. Medicare and insurance providers increasingly reimburse point-of-care tests, with US$ 14.2 billion allocated for home-based diagnostic services in 2024 alone. Major healthcare systems are investing heavily in decentralized testing infrastructure, exemplified by Kaiser Permanente's US$ 500 million initiative to deploy 15,000 point-of-care devices across their facilities by 2026. The global point-of-care testing market benefits from technological innovations specifically designed for elderly patients, including simplified interfaces, larger displays, and automated result transmission to healthcare providers. Companies like Abbott and Roche have introduced specialized product lines targeting geriatric care, with combined investments exceeding US$ 2.3 billion in age-specific diagnostic development. This demographic shift fundamentally transforms healthcare delivery models, making rapid, accessible testing essential for managing the growing elderly population's complex health needs.

Trend: Shift From Centralized Laboratories To Decentralized Patient Care Settings

The global point-of-care testing market is undergoing a fundamental transformation as healthcare providers migrate from centralized laboratory models to distributed diagnostic networks across diverse care settings. This decentralization movement has accelerated dramatically, with 68,000 healthcare facilities worldwide implementing point-of-care testing programs in 2024, compared to 42,000 in 2020. The shift is driven by the need for immediate clinical decision-making, with traditional laboratory turnaround times averaging 24 to 48 hours versus 15 minutes for point-of-care tests. Healthcare systems are reallocating substantial resources, with US$ 18.7 billion invested globally in decentralized testing infrastructure during 2024. Emergency departments lead this transition, with 8 out of 10 facilities now utilizing bedside diagnostics for critical parameters. The global point-of-care testing market expansion reflects changing care delivery models, where pharmacies, urgent care centers, and even retail clinics now perform complex diagnostic procedures previously exclusive to hospitals.

Technological advancements enable this decentralization, with miniaturized devices delivering laboratory-quality results in non-traditional settings. Cloud-based connectivity allows 45,000 decentralized testing sites to transmit results directly to electronic health records, ensuring continuity of care across locations. Major health systems report significant operational improvements, with Cleveland Clinic documenting 3.2 hour reductions in emergency department stays through point-of-care implementation. The economic impact is substantial, with decentralized testing reducing healthcare costs by US$ 127 per patient encounter through eliminated transportation, reduced hospital admissions, and faster treatment initiation. In the global point-of-care testing market, innovative delivery models emerge, including mobile health units serving 12 million patients in underserved areas and workplace wellness programs conducting 85 million tests annually. This paradigm shift represents healthcare's evolution toward patient-centric models, where diagnostics occur at the moment and location of need rather than requiring patients to navigate complex healthcare infrastructure.

Challenge: Data Privacy Concerns Hindering Digital Health Platform Integration Efforts

The global point-of-care testing market faces significant obstacles as data privacy concerns create barriers to seamless digital health integration, with 73 countries implementing stringent regulations affecting diagnostic data transmission. Healthcare organizations report spending US$ 39.6 billion annually on cybersecurity measures specifically related to diagnostic data protection, reflecting the magnitude of privacy challenges. Major data breaches affecting 42 million patient records in 2024 have heightened concerns about point-of-care device connectivity, leading to increased scrutiny from regulators and patients alike. The implementation of GDPR in Europe, HIPAA in the United States, and similar frameworks across Asia-Pacific markets requires diagnostic manufacturers to invest US$ 8.2 billion in compliance infrastructure. Healthcare providers express reluctance to adopt fully connected systems, with 4,200 hospitals delaying digital integration projects due to unresolved security concerns. The global point-of-care testing market must navigate complex regulatory landscapes while maintaining the real-time data sharing capabilities essential for effective patient care.

The intersection of diagnostic innovation and privacy protection creates operational challenges that directly impact market growth and adoption rates. Point-of-care device manufacturers allocate 18 cents of every revenue dollar to address privacy and security requirements, significantly affecting product pricing and accessibility. Healthcare systems report that privacy-related implementation delays average 8.4 months, during which facilities continue using less efficient traditional methods. Emerging solutions include blockchain-based data management systems, with US$ 2.7 billion invested in secure diagnostic data platforms during 2024. Major technology partnerships, such as Microsoft's collaboration with 15 diagnostic companies, aim to create privacy-preserving architectures that satisfy regulatory requirements while enabling clinical benefits. In the global point-of-care testing market, successful navigation of privacy challenges determines competitive advantage, as providers seek solutions balancing patient data protection with operational efficiency and clinical effectiveness in an increasingly connected healthcare ecosystem.

Segmental Analysis 

Testing Kits & Consumables to Continue Leading the Market With over 65.55% Market Share

Testing kits and consumables dominate the global point-of-care testing market due to their recurring purchase nature and essential role in diagnostic procedures, with each test requiring fresh supplies regardless of equipment availability. The most prominent consumables include glucose test strips, generating US$ 12.8 billion in annual revenue, lateral flow immunoassay cartridges worth US$ 8.4 billion, and blood gas analysis cartridges commanding US$ 3.2 billion globally. Coagulation monitoring strips, pregnancy test kits, and cardiac marker cassettes collectively contribute another US$ 9.7 billion to the consumables segment. Unlike equipment that requires one-time capital investment lasting 5-7 years, consumables generate continuous revenue streams as healthcare facilities perform millions of tests daily. Major hospitals report spending US$ 2.4 million annually on consumables versus US$ 800,000 on equipment amortized over multiple years.

The consumables segment benefits from technological innovations that enhance test accuracy while reducing costs, making them increasingly accessible across healthcare settings. Advanced manufacturing processes have reduced production costs by US$ 0.82 per unit since 2020, enabling broader market penetration. In the global point-of-care testing market, consumables maintain higher profit margins, with manufacturers reporting 4.2 times greater returns compared to equipment sales The shift toward value-based healthcare models drives consumables adoption, as providers seek cost-effective solutions for routine testing. Strategic partnerships between manufacturers and healthcare systems ensure steady consumables supply, with long-term contracts worth US$ 18.3 billion signed in 2024 alone. This dominance reflects the fundamental healthcare reality that while equipment provides the platform, consumables deliver the actual diagnostic capability required for patient care.

Immunological PoC Tests Market Leadership to Continue Contributing Over 41.41% Market Revenue 

Immunological point-of-care tests command significant market share in the global point-of-care testing market by addressing critical diagnostic needs across infectious diseases, cardiac conditions, and pregnancy monitoring with rapid, accurate results Major immunological tests include rapid HIV antibody tests processing 89 million samples annually, hepatitis screening assays conducting 67 million tests, and COVID-19 antigen tests performing over 1.2 billion analyses worldwide. Cardiac troponin tests, utilized in 45 million emergency department visits yearly, enable immediate heart attack diagnosis, while pregnancy tests remain the highest volume consumer application with 380 million units sold annually. These tests leverage antibody-antigen interactions to deliver results within 15 minutes, eliminating laboratory delays that could compromise patient outcomes. The technology's versatility allows adaptation across multiple disease states, creating economies of scale that reduce per-test costs to US$ 2.85 compared to US$ 18.50 for laboratory equivalents.

Key end-users driving immunological test demand include emergency departments performing 127 million annual tests, primary care clinics conducting 203 million screenings, and community health centers processing 94 million tests in underserved areas. The global point-of-care testing market benefits from immunological tests' simplicity, requiring minimal training for healthcare workers to achieve laboratory-comparable accuracy Regulatory approvals accelerate market growth, with 234 new immunological tests receiving clearance in 2024 across major markets. Investment in immunological test development reached US$ 4.7 billion in 2024, focusing on multiplex panels that simultaneously detect multiple pathogens. Healthcare systems report US$ 156 average savings per patient through immunological point-of-care testing, combining reduced laboratory costs, faster treatment initiation, and decreased hospital stays, solidifying these tests' position as essential diagnostic tools.

Infectious Diseases Indication Dominance to Stay Leading with Over 31.30% Market Share

Infectious diseases represent the largest indication in the global point-of-care testing market due to their acute nature requiring immediate diagnosis and treatment initiation to prevent transmission and complications. Global infectious disease burden remains substantial, with 1.6 billion respiratory infections, 296 million hepatitis B cases, 58 million hepatitis C infections, and 38.4 million HIV cases driving continuous testing demand. Annual testing volumes reach staggering numbers: 2.8 billion tests for respiratory pathogens, 890 million sexually transmitted infection screenings, and 1.4 billion gastrointestinal pathogen tests performed worldwide. The COVID-19 pandemic fundamentally transformed infectious disease testing paradigms, establishing decentralized diagnostics as standard practice rather than emergency response. Healthcare systems now maintain permanent point-of-care testing infrastructure, with US$ 23.7 billion invested in infectious disease diagnostic capacity during 2023-2024.

The segment's dominance stems from multiple factors including disease transmissibility, public health mandates, and treatment urgency that cannot accommodate traditional laboratory turnaround times. Rapid identification enables immediate isolation protocols, targeted therapy, and contact tracing, particularly critical in densely populated areas where 4.4 billion people face elevated transmission risks. In the global point-of-care testing market, infectious disease applications benefit from continuous innovation, with molecular diagnostics reducing detection times from days to 20 minutes Government funding programs allocate US$ 31.2 billion globally for infectious disease surveillance and testing, ensuring sustainable market growth. Emerging infectious disease threats, antimicrobial resistance patterns requiring 156 million susceptibility tests annually, and seasonal epidemics affecting 1 billion people maintain constant demand. This combination of high disease prevalence, public health imperatives, and technological advancement cements infectious diseases' position as the dominant point-of-care testing indication.

Prescription-Based Testing Control the Largest 53.2% Market Share

Prescription-based testing maintains dominance in the global point-of-care testing market through regulatory requirements ensuring appropriate test utilization and clinical oversight for complex diagnostic procedures Major prescription-based tests include hemoglobin A1c monitoring for 537 million diabetics worldwide, generating US$ 8.9 billion annually; anticoagulation monitoring through PT/INR testing for 42 million patients, worth US$ 3.4 billion; and comprehensive metabolic panels performed 267 million times yearly, representing US$ 5.8 billion in market value. Cardiac biomarker panels, thyroid function tests, and specialized infectious disease confirmatory assays collectively add US$ 11.2 billion to prescription-based revenues. Healthcare systems mandate physician authorization to prevent inappropriate testing, ensure proper result interpretation, and maintain quality standards that protect patient safety while optimizing resource utilization.

The prescription model's dominance reflects healthcare's professional oversight requirements and reimbursement structures that tie payment to physician orders. Insurance providers processed US$ 28.7 billion in prescription-based point-of-care test claims during 2024, while denying 3.8 million unauthorized test reimbursements. Clinical guidelines from 47 major medical societies specify prescription requirements for diagnostic tests affecting treatment decisions. In the global point-of-care testing market, prescription-based testing benefits from integrated electronic health records that streamline ordering, result reporting, and clinical decision support. Regulatory frameworks in 82 countries mandate prescription requirements for tests with significant clinical implications, reinforcing market dynamics. The model ensures continuity of care, with 94 million test results automatically transmitted to ordering physicians for interpretation and follow-up, maintaining healthcare quality standards while supporting the growing demand for decentralized diagnostics.

 To Understand More About this Research:  Request A Free Sample 

Regional Analysis 

North America: The Largest Point-of-Care Testing Market

North America dominates the global point-of-care testing market with revenues exceeding US$ 18,648.82 million in 2024, driven by advanced healthcare infrastructure, high per-capita healthcare spending of US$ 12,914 annually, and widespread insurance coverage affecting 287 million individuals. The region benefits from robust regulatory frameworks facilitating rapid product approvals, with the FDA clearing 67 new point-of-care devices in 2024 alone. Major healthcare systems including Mayo Clinic, Cleveland Clinic, and Johns Hopkins have invested US$ 3.8 billion collectively in point-of-care infrastructure, establishing 45,000 testing sites across hospitals, clinics, and pharmacies. The presence of leading manufacturers such as Abbott, Danaher, and Thermo Fisher Scientific, headquartered in the region, creates innovation ecosystems generating 234 patents annually. Additionally, government initiatives allocating US$ 8.7 billion for diagnostic preparedness and Medicare reimbursements covering 42 million beneficiaries ensure sustained market growth.

United States: The Largest Single Country Market

The United States represents the largest single-country global point-of-care testing market by performing 1.8 billion tests annually across 6,090 hospitals and 238,000 physician offices. American healthcare's unique dynamics, including immediate diagnostic expectations and litigation concerns driving defensive medicine practices, result in 3.2 tests per capita annually compared to 1.7 in other developed nations. The country's investment in diagnostic innovation reaches US$ 5.4 billion yearly, with Silicon Valley and Boston emerging as diagnostic technology hubs housing 312 point-of-care startups. Major retail pharmacy chains CVS, Walgreens, and Walmart operate 21,000 locations offering point-of-care services, democratizing access for 198 million Americans. Federal programs including BARDA provide US$ 2.1 billion in funding for next-generation diagnostic development, maintaining technological leadership.

Asia Pacific: The Fastest Growing Regional Market

Asia Pacific emerges as the fastest-growing region in the global point-of-care testing market at a CAGR of 8.27%, with investments reaching US$ 5 billion in 2024 as countries modernize healthcare infrastructure to serve 4.6 billion residents China leads regional expansion with 34,000 new primary care centers implementing point-of-care diagnostics, while India's Ayushman Bharat program covers 500 million citizens requiring accessible testing. Japan's aging society of 36 million elderly drives sophisticated home-testing adoption worth US$ 3.2 billion annually. Southeast Asian nations collectively invested US$ 6.7 billion in diagnostic capabilities, with Indonesia, Thailand, and Vietnam establishing 12,000 rural testing facilities. The region benefits from local manufacturing reducing costs by US$ 4.30 per test, technology transfer agreements worth US$ 2.8 billion, and government mandates requiring point-of-care capabilities in 156,000 healthcare facilities, positioning Asia Pacific to surpass North America by 2033.

Top Companies in the Point of Care Testing Market

• Abbott Laboratories
• F. Hoffmann-La Roche Ltd
• Danaher Corporation
• Becton, Dickinson and Company (BD)
• bioMérieux SA
• Bio-Rad Laboratories, Inc.
• Other Prominent Players

Market Segmentation Overview

By Product

• Devices & Instruments
  • Diagnostic Analyzers & Testing Devices
    • Blood Gas & Electrolyte Analyzers
    • Cardiac Biomarker Analyzers
    • Glucose Monitoring Devices
    • Coagulation Testing Analyzers
    • Urinalysis Analyzers
    • Routine Clinical Chemistry Analyzers
    • Others
  • Monitoring Devices
    • Blood Pressure Monitors
    • Thermometers
    • Pulse Oximeters
    • Others
• Testing Kits & Consumables
  • Blood Gas & Electrolyte Test Kits
  • Cardiac Biomarker Test Kits
  • Routine Clinical Chemistry Test Kits
  • Hematology Test Kits Coagulation Testing Kits
  • Urinalysis Test Strips & Kits
  • Cholesterol Test Strips
  • Drugs Abuse Testing Kits
  • Pregnancy And Fertility Testing Kits
  • Others

By Test Type

• Immunological PoC Tests
• Nucleic Acid-Based PoC Tests
• Biomarker-Based PoC Tests

 By Indication

• Infectious Diseases
  • HIV
  • COVID-19
  • Others
• Oncology
• Cardiovascular Diseases
• Metabolic Disorders
• Respiratory Diseases
• Neurological Disorders
• Gastrointestinal Disorders
• Others

By Technology

• Biosensor Technology
• Microfluidic Lab-On-A-Chip Technology
• Molecular Diagnostics
• Immunoassays
• Others

By Sample Type

• Blood
• Urine
• Saliva
• Others

By Mode Of Purchase

• Prescription-based Testing
• Over the Counter (OTC) Testing

By End User

• Hospitals & Clinics
• Diagnostic Centers
• Homecare Settings
• Research Laboratories
• Others

By Distribution Channel

• Direct Distribution
• Retail Pharmacies
• Online Pharmacies
• Others

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • Western Europe
    • The UK
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Western Europe
  • Eastern Europe
    • Poland
    • Russia
    • Hungary
    • Rest of Eastern Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia & New Zealand
  • ASEAN
  • Rest of Asia Pacific
• Middle East
  • UAE
  • Saudi Arabia
  • Bahrain
  • Kuwait
  • Qatar
  • Rest of Middle East
• Africa
  • Morocco
  • Egypt
  • Nigeria
  • South Africa
  • Rest of Africa
• South America
  • Argentina
  • Brazil
  • Rest of South America